<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">82973</article-id><article-id pub-id-type="doi">10.26442/00403660.2021.09.201033</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prognostic impact of uric acid in patients with acute decompensated heart failure</article-title><trans-title-group xml:lang="ru"><trans-title>Значимость мочевой кислоты для клинических исходов у пациентов с острой декомпенсацией хронической сердечной недостаточности</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0920-7417</contrib-id><name-alternatives><name xml:lang="en"><surname>Nasonova</surname><given-names>Svetlana N.</given-names></name><name xml:lang="ru"><surname>Насонова</surname><given-names>Светлана Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, ст. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности ФГБУ «НМИЦ кардиологии»</p></bio><email>anastasiyalapteva95@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9260-9520</contrib-id><name-alternatives><name xml:lang="en"><surname>Lapteva</surname><given-names>Anastasiya E.</given-names></name><name xml:lang="ru"><surname>Лаптева</surname><given-names>Анастасия Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>клин. ординатор отд. заболеваний миокарда и сердечной недостаточности ФГБУ «НМИЦ кардиологии»</p></bio><email>anastasiyalapteva95@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4066-2661</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhirov</surname><given-names>Igor V.</given-names></name><name xml:lang="ru"><surname>Жиров</surname><given-names>Игорь Витальевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, вед. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности ФГБУ «НМИЦ кардиологии», проф. каф. кардиологии ФГБОУ ДПО РМАНПО</p></bio><email>anastasiyalapteva95@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2236-3959</contrib-id><name-alternatives><name xml:lang="en"><surname>Mindzaev</surname><given-names>Dzambolat R.</given-names></name><name xml:lang="ru"><surname>Миндзаев</surname><given-names>Дзамболат Роланович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант отд. заболеваний миокарда и сердечной недостаточности ФГБУ «НМИЦ кардиологии»</p></bio><email>anastasiyalapteva95@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9234-6129</contrib-id><name-alternatives><name xml:lang="en"><surname>Tereshchenko</surname><given-names>Sergey N.</given-names></name><name xml:lang="ru"><surname>Терещенко</surname><given-names>Сергей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф., рук. отд. заболеваний миокарда и сердечной недостаточности ФГБУ «НМИЦ кардиологии», зав. каф. кардиологии ФГБОУ ДПО РМАНПО</p></bio><email>anastasiyalapteva95@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center of Cardiology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2021</year></pub-date><volume>93</volume><issue>9</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>1066</fpage><lpage>1072</lpage><history><date date-type="received" iso-8601-date="2021-10-09"><day>09</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-09"><day>09</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/82973">https://ter-arkhiv.ru/0040-3660/article/view/82973</self-uri><abstract xml:lang="en"><p><bold>Aim</bold>. To evaluate the prognostic impact of serum uric acid (SUA) on clinical outcomes in patients with acute decompensated heart failure, as well as identify the correlation between hyperuricemia and renal function and diuretic resistance in these patients.</p> <p><bold>Materials and methods</bold>. The study included 175 patients (125 men and 50 women) with NYHA class II–IV acute decompensated heart failure. Median age was 64 (56–75) years. The Information regarding the survival was obtained 3 years after the admission by telephone calls.</p> <p><bold>Results</bold>. 57 patients reached the end point (death from all causes); therefore, all patients were divided into groups: "alive", "dead". The SUA levels did not differ in the groups. The only significant difference in the studied parameters was the estimated glomerular filtration rate (eGFR), which was significantly higher in the "alive" group [70.5 (52.8–94) and 56 (40–79), respectively; p=0.006]. A moderate negative correlation was found between SUA levels and eGFR in the correlation analysis (r=-0.313, p&lt;0.001). A comparative analysis showed, that SUA level on admission was significantly higher in patients who subsequently received increased doses of diuretics than in patients with a satisfactory response to standard doses of diuretics [567.8 (479.6–791.9) and 512 (422.4–619.4), respectively; p=0.011]. Also, higher eGFR level on admission was observed in patients from the normal SUA level group than in patients from the hyperuricemia group [94 (74.5–101.5) and 63 (48.8–81.3), respectively; p=0.002].</p> <p><bold>Conclusion</bold>. We found no significant differences in the uric acid level in patients who reached the end point and those who did not reach it during the three-year follow-up. However, the found correlation between uric acid levels and diuretic resistance calls for further research.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель</bold>. Оценить значимость мочевой кислоты (МК) в крови для клинических исходов у пациентов с острой декомпенсацией хронической сердечной недостаточности (ОДХСН), а также определить связь гиперурикемии с фильтрационной функцией почек и с резистентностью к диуретической терапии.</p> <p><bold>Материалы и методы</bold>. В исследование включены 175 пациентов (125 мужчин, 50 женщин) с ОДХСН II–IV функционального класса (NYHA), медиана возраста – 64 (56–75) года. Определение отдаленного прогноза производилось через 3 года от момента госпитализации посредством телефонных звонков.</p> <p><bold>Результаты</bold>. Конечной точки (смерть от всех причин) достигли 57 пациентов, что позволило разделить исследуемых на группы: «живые», «умершие». Уровень МК не отличался среди пациентов исследуемых групп. Скорость клубочковой фильтрации (СКФ) достоверно выше в группе «живые» [70,5 (52,8–94) и 56 (40–79) соответственно; р=0,006]. При проведении корреляционного анализа выявлена отрицательная связь средней силы между уровнем МК и СКФ (r=-0,313, p&lt;0,001). При проведении сравнительного анализа уровень МК при поступлении в стационар достоверно выше у больных, которым в дальнейшем производилось усиление терапии, в сравнении с пациентами с удовлетворительным ответом на стандартные дозы диуретиков [567,8 (479,6–791,9) и 512 (422,4–619,4) соответственно; р=0,011]. Более высокий уровень СКФ при поступлении наблюдался у пациентов в группе с нормальным уровнем МК по сравнению с пациентами из группы гиперурикемии [94 (74,5–101,5) и 63 (48,8–81,3) соответственно; р=0,002].</p> <p><bold>Заключение</bold>. В исследовании не продемонстрировано достоверных различий уровня МК у пациентов, достигших конечной точки, и тех, кто ее не достиг в течение 3-летнего периода наблюдения. Однако связь между уровнем МК и резистентностью к диуретической терапии, выявленная в исследовании, представляет интерес для дальнейшего изучения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>acute decompensated heart failure</kwd><kwd>hyperuricemia</kwd><kwd>serumuric acid</kwd><kwd>diuretic therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>острая декомпенсация хронической сердечной недостаточности</kwd><kwd>гиперурикемия</kwd><kwd>мочевая кислота</kwd><kwd>диуретическая терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Chong VH, Singh J, Parry H, et al. Management of Noncardiac Comorbidities in Chronic Heart Failure. Cardiovasc Ther. 2015;33(5):300-15. DOI:10.1111/1755-5922.12141</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Рос. кардиол. журн. 2016;(8):7-13 [Fomin IV. Chronic heart failure in russian federation: What do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13 (in Russian)]. DOI:10.15829/1560-4071-2016-8-7-13</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16(1):103-11. DOI:10.1002/ejhf.30</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, et al. JCARE-CARD Investigators. Hyperuricemia predicts adverse outcomes in patients with heart failure. J Cardiol. 2011;151(2):143-7. DOI:10.1016/j.ijcard.2010.05.002</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Martinez A, Gonzalez A, Cerda C, et al. Prognostic value of hyperuricemia in chronic heart failure. Rev Med Chil. 2004;132(9):1031-6. DOI:10.4067/s0034-98872004000900002</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:19917. DOI:10.1161/01.CIR.0000065637.10517.A0</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2010; с. 720 [Rheumatology: national guidelines. Eds. EL Nasonov, VA Nasonova. Moscow: GEOTAR-Media, 2010; p. 720 (in Russian)].</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, et al. Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol. 2011;151:143-7. DOI:10.1016/j.ijcard.2010.05.002</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hare J, Johnson R. Uric acid predicts clinical outcomes in heart failure. Insights regarding the role of xantine oxidase and uric acid in disease pathophysiology. Circulation. 2003;107:1951-3. DOI:10.1161/01.CIR.0000066420.36123.35</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zhang Z, Bian L, Choi Y. Serum uric acid: A marker of metabolic syndrome and subclinical atherosclerosis in Korean men. Angiology. 2012;63:420-8. DOI:10.1177/0003319711423806</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of incident hypertension: A systematic review and meta-analysis of observational studies. PLoS One. 2014;9(12):e114259. DOI:10.1371/journal.pone.0114259</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Krishnan E, Pandya BJ, Chung L, et al. Hyperuricemia and the risk for subclinical coronary atherosclerosis – data from a prospective observational cohort study. Arthritis Res Ther. 2011;13:R66. DOI:10.1186/ar3322</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Billiet L, Doaty S, Katz JD, et al. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol. 2014;2014:852954. DOI:10.1155/2014/852954</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Choi BG, Kim DJ, Baek MJ, et al. Hyperuricaemia and development of type 2 diabetes mellitus in Asian population. Clin Exp Pharmacol Physiol. 2018;45:499-506. DOI:10.1111/1440-1681.12911</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16(1):15-24. DOI:10.1093/eurjhf/hft132</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Palazzuoli A, Ruocco G, Pellegrini M, et al. Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure. Am J Cardiol. 2016;117(10):1616-21. DOI:10.1016/j.amjcard.2016.02.039</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Grossman C, Grossman E, Goldbourt U. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. PLoS One. 2019;14(8):e0220532. DOI:10.1371/journal.pone.0220532</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wattad M, Darawsha W, Solomonica A, et al. Interaction between worsening renal function and persistent congestion in acute decompensated heart failure. Am J Cardiol. 2015;115(7):932-7. DOI:10.1016/j.amjcard.2015.01.019</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5(1):54-62. DOI:10.1161/CIRCHEARTFAILURE.111.963413</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Резник Е.В. Состояние почечной гемодинамики и функции почек у больных с хронической сердечной недостаточностью. М., 2007; с. 161 [Reznik EV. Sostoyanie pochechnoj gemodinamiki i funkcii pochek u bol'nyh s hronicheskoj serdechnoj nedostatochnost'yu. Moscow, 2007; p. 161 (in Russian)].</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Серов В.А., Шутов А.М., Сучков В.Н., и др. Прогностическое значение снижения функции почек у больных с хронической сердечной недостаточностью. Нефрология и диализ. 2008;10:3-4 [Serov VA, Shutov AM, Suchkov VN, et al. Decrease of kidney function and prognosis in patients with chronic heart failure. Nephrology and Dialysis. 2008;10:3-4 (in Russian)].</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ларина В.Н., Барт Б.Я., Ларин В.Г., Донсков А.С. Высокая концентрация сывороточной мочевой кислоты: клиническое и прогностическое значение при хронической сердечной недостаточности. Кардиология. 2016;5:68-75 [Larina VN, Bart BY, Larin VG, Donskov AS. High Serum Concentrations of Uric Acid: Clinical and Prognostic Significance in Chronic Heart Failure. Kardiologiia. 2016;56(5):68-75 (in Russian)]. DOI:10.18565/cardio.2016.5.68-75</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67(1):23747. DOI:10.1111/j.1523-1755.2005.00074.x</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888-97. DOI:10.1097/01.asn.0000034910.58454.fd</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal – independent mechanism. Hypertension. 2001;38(5):1101-6. DOI:10.1161/hy1101.092839</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Ледяхова М.В., Насонова С.Н., Терещенко С.Н. Гиперурикемия как предиктор хронической сердечной недостаточности. Рацион. фармакотерапия в кардиологии. 2015;11(4):355-8 [Ledyakhova MV, Nasonova SN, Tereshchenko SN. Hyperuricemia as a predictor of chronic heart failure. Ration Pharmacother Cardiol. 2015;11(4):355-8 (in Russian)].</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016:37:2129-200. DOI:10.1093/eurheartj/ehw128</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Zhou HB, Xu TY, Liu SR, et al. Association of serum uric acid change with mortality, renal function and diuretic dose administered in treatment of acute heart failure. Nutr Metab Cardiovasc Dis. 2019;29(4):351-9. DOI:10.1016/j.numecd.2019.01.001</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Neuberg GW, Miller AB, O'Connor CM, et al. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144(1):31-8. DOI:10.1067/mhj.2002.123144</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7(2):261-70. DOI:10.1161/CIRCHEARTFAILURE.113.000895</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Palazzuoli A, Testani JM, Ruocco G, et al. Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance. Int J Cardiol. 2016;224:213-9. DOI:10.1016/j.ijcard.2016.09.005</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Valente MA, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014;35(19):1284-93. DOI:10.1093/eurheartj/ehu065</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Chiu TH, Wu PY, Huang JC, et al. Hyperuricemia Is Associated with Left Ventricular Dysfunction and Inappropriate Left Ventricular Mass in Chronic Kidney Disease. Diagnostics (Basel). 2020;10(8):514. DOI:10.3390/diagnostics10080514</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Palazzuoli A, Ruocco G, De Vivo O, et al. Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. Am J Cardiol. 2017;120(7):1146-50. DOI:10.1016/j.amjcard.2017.06.057</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Krishnan E, Akhras KS, Sharma H, et al. Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM. 2013;106(8):721-9. DOI:10.1093/qjmed/hct093</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Juraschek SP, McAdams-Demarco M, Miller ER, et al. Temporal relationship between uric acid concentration and risk of diabetes in a community-based study population. Am J Epidemiol. 2014;179(6):684-91. DOI:10.1093/aje/kwt320</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Liu J, Tao L, Zhao Z, et al. Two-year changes in hyperuricemia and risk of diabetes: a five-year prospective cohort study. J Diabetes Res. 2018;2018:1-7. DOI:10.1155/2018/6905720</mixed-citation></ref></ref-list></back></article>
